Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies

Inclusion Criteria: * Written informed consent obtained. * Age ≥ 18 years at the time of study entry. * Histological or Cytologically diagnosed gynecological malignancies. * Failure to prior standard treatment (surgery, chemotherapy, radiotherapy); * Refractory/recurrence/metastasis gynecological cancer * At least one measurable lesion according to the RECIST1.1. * Cooperative Oncology Group-Status (ECOG Status) 0-3. * The last treatment should be over 2 weeks. Exclusion Criteria: * History or evidence of active autoimmune disease that requires systemic treatment. * Participated in other anti-tumor clinical trials within 4 weeks. * Patients who have a contraindication to similar drugs. * That failure to follow up regularly.